Jin, Jing
Tarrant, Richard D.
Bolam, Emma J.
Angell-Manning, Philip
Soegaard, Max
Pattinson, David J.
Dulal, Pawan
Silk, Sarah E.
Marshall, Jennifer M.
Dabbs, Rebecca A.
Nugent, Fay L.
Barrett, Jordan R.
Hjerrild, Kathryn A.
Poulsen, Lars
Jørgensen, Thomas http://orcid.org/0000-0002-4868-8735
Brenner, Tanja
Baleanu, Ioana N.
Parracho, Helena M.
Tahiri-Alaoui, Abdessamad
Whale, Gary
Moyle, Sarah
Payne, Ruth O.
Minassian, Angela M.
Higgins, Matthew K.
Detmers, Frank J.
Lawrie, Alison M.
Douglas, Alexander D.
Smith, Robert
de Jongh, Willem A.
Berrie, Eleanor
Ashfield, Rebecca
Draper, Simon J. http://orcid.org/0000-0002-9415-1357
Funding for this research was provided by:
Medical Research Council (MR/K025554/1)
Wellcome Trust (106917/Z/15/Z, 201477/Z/16/Z)
Lister Institute of Preventive Medicine (Draper Prize Fellowship)
Article History
Received: 20 March 2018
Revised: 29 May 2018
Accepted: 1 June 2018
First Online: 17 August 2018
Competing interests
: A.D.D., M.K.H., and S.J.D. are named inventors on patent applications relating to PfRH5 and/or other malaria vaccines. M.S., L.P., T.J., and W.A.d.J. are employees of and W.A.d.J. is a shareholder in ExpreS<sup>2</sup>ion Biotechnologies, which has developed and is marketing the ExpreS<sup>2</sup> cell expression platform. F.J.D. is an employee of Thermo Fisher Scientific who is the commercial provider of CaptureSelectâ„¢ C-tag products. The remaining authors declare no competing interests.